A multi-omics paper proposes a possible lorazepam-related target but does not establish that lorazepam treats or causes ovarian cancer.
Computational analyses identified overlap between predicted drug-related genes and ovarian-cancer data, highlighting PTK2. Laboratory experiments then reduced PTK2 expression in cancer cells and measured growth, migration, and apoptosis. Public tumor datasets supplied additional associations.
Knocking down a gene is not the same intervention as administering lorazepam. Predicted target overlap and tumor-gene associations cannot prove that clinical drug exposure produces the same effect. The authors acknowledged that much of the analysis was associative and computational.
For an expert discussion, separate the molecule, predicted target, experimental manipulation, and clinical claim. This paper generates mechanistic hypotheses. It supplies no patient-level evidence that a benzodiazepine prescription altered cancer progression, survival, or an individual’s cancer risk.
Source reviewed: Integrative multi omics and experimental analyses implicate PTK2 as a lorazepam associated biomarker (PMC12876144). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Three-Drug ERCP Sedation Compared Age Groups Rather Than Isolated Medicines; Lorazepam NMS Review Drew From Case Reports Rather Than Controlled Trials.